Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 3/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5220157 | 0.90 | NOD2 (0.36) | NOD2NOD1SMN1; SMN2TP53POLB | |
| SCHEMBL5221628 | 0.88 | POLB (0.35) | NOD2NOD1SMN1; SMN2TP53POLB | |
| SCHEMBL5220154 | 0.82 | KMT2A (0.39) | NOD2NOD1SMN1; SMN2TP53POLB | |
| SCHEMBL32673777 | 0.81 | HSP90AA1 (0.34) | POLBMEN1KMT2A | |
| SCHEMBL5223527 | 0.81 | NOD2 (0.36) | NOD2NOD1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5220970 | 0.80 | NOD2 (0.40) | NOD2NOD1SMN1; SMN2TP53POLB | |
| SCHEMBL5761257 | 0.80 | NOD2 (0.40) | NOD2NOD1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2875438 | 0.79 | NOD2 (0.37) | NOD2NOD1SMN1; SMN2TP53POLB | |
| SCHEMBL5219482 | 0.79 | NOD2 (0.39) | NOD2NOD1SMN1; SMN2TP53POLB | |
| SCHEMBL5222402 | 0.79 | NOD2 (0.35) | NOD2NOD1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100400538-C | 5HT for the treatment of diabetes and obesity2cReceptor agonists | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | CN | disclosed |
| EP-1641796-B1 | 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | HOFFMANN LA ROCHE (CH) | 2007-06-06 | — | — | EP | disclosed |
| US-7208494-B2 | 5HT2c receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| CN-1812989-A | 5ht2c receptor agonists for the treatment of diabetes and obesity | HOFFMANN LA ROCHE (CH) | 2006-08-02 | — | — | CN | disclosed |
| EP-1641796-A1 | 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-05 | — | — | EP | disclosed |
| US-20050026925-A1 | 5HT2c receptor agonists | HOFFMANN-LA ROCHE INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2005000849-A1 | 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026925-A1 | 5HT2c receptor agonists | HTR2C, HTR2A, HTR5A | NOD2 2274/4885NOD1 2471/4885SMN1; SMN2 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.